PDCD1 and melanoma: But there still exist some limitations of ICIs, the response rates of patients treated with anti-PD-1 antibody are relatively low in several types of cancer (approximately 20 to 25% in non–small-cell lung cancer, melanoma, or renal-cell cancer) (15).